Crossmark

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma

Crossref DOI link: https://doi.org/10.1186/s40364-019-0160-4

Published Online: 2019-04-11

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aujla, Amandeep

Aujla, Ravijot

Liu, Delong http://orcid.org/0000-0003-4502-4949
License Information

Text and Data Mining valid from 2019-04-11
More Information

Article History

Received: 18 February 2019

Accepted: 27 March 2019

First Online: 11 April 2019

Ethics approval and consent to participate

: This is not applicable for this review.

: This is not applicable for this review.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.